Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !
Sun Pharmaceutical Industries Management
Management Kriterienprüfungen 4/4
Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.
Wichtige Informationen
Dilip Shanghvi
Geschäftsführender
₹54.5m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 75.2% |
| Amtszeit als Geschäftsführer | 31.3yrs |
| Eigentum des Geschäftsführers | 9.6% |
| Durchschnittliche Amtszeit des Managements | 2.4yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 3.1yrs |
Jüngste Management Updates
Recent updates
Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year
May 25
Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Price Is Out Of Tune With Earnings
May 22Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Mar 13Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Feb 03Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Might Deserve Your Attention Today
Jan 05Getting In Cheap On Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Is Unlikely
Dec 18Is Now The Time To Put Sun Pharmaceutical Industries (NSE:SUNPHARMA) On Your Watchlist?
Oct 04Should You Be Adding Sun Pharmaceutical Industries (NSE:SUNPHARMA) To Your Watchlist Today?
Jul 03We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Can Manage Its Debt With Ease
Jun 15Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) A Risky Investment?
Mar 14Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Increasing Its Dividend To ₹7.50
Feb 03These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Reasonably Well
Dec 09Does This Valuation Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Imply Investors Are Overpaying?
Oct 13These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Safely
Sep 04Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Aug 05Estimating The Intrinsic Value Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
Jul 12Does Sun Pharmaceutical Industries (NSE:SUNPHARMA) Have A Healthy Balance Sheet?
Jun 02Is Now The Time To Put Sun Pharmaceutical Industries (NSE:SUNPHARMA) On Your Watchlist?
Apr 28Are Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Investors Paying Above The Intrinsic Value?
Apr 09Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Increasing Its Dividend To ₹7.00
Feb 02Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) Using Too Much Debt?
Feb 02Should You Be Adding Sun Pharmaceutical Industries (NSE:SUNPHARMA) To Your Watchlist Today?
Jan 19Estimating The Intrinsic Value Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
Dec 27Sun Pharmaceutical Industries (NSE:SUNPHARMA) Seems To Use Debt Rather Sparingly
Nov 04Here's Why I Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Might Deserve Your Attention Today
Oct 21Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | ₹96b |
| Dec 31 2023 | n/a | n/a | ₹89b |
| Sep 30 2023 | n/a | n/a | ₹85b |
| Jun 30 2023 | n/a | n/a | ₹84b |
| Mar 31 2023 | ₹55m | ₹41m | ₹85b |
| Dec 31 2022 | n/a | n/a | ₹42b |
| Sep 30 2022 | n/a | n/a | ₹41b |
| Jun 30 2022 | n/a | n/a | ₹39b |
| Mar 31 2022 | ₹51m | ₹38m | ₹33b |
| Dec 31 2021 | n/a | n/a | ₹64b |
| Sep 30 2021 | n/a | n/a | ₹62b |
| Jun 30 2021 | n/a | n/a | ₹60b |
| Mar 31 2021 | ₹46m | ₹35m | ₹29b |
| Dec 31 2020 | n/a | n/a | ₹24b |
| Sep 30 2020 | n/a | n/a | ₹15b |
| Jun 30 2020 | n/a | n/a | ₹7b |
| Mar 31 2020 | ₹43m | ₹32m | ₹38b |
| Dec 31 2019 | n/a | n/a | ₹40b |
| Sep 30 2019 | n/a | n/a | ₹43b |
| Jun 30 2019 | n/a | n/a | ₹30b |
| Mar 31 2019 | ₹263k | ₹1 | ₹27b |
| Dec 31 2018 | n/a | n/a | ₹34b |
| Sep 30 2018 | n/a | n/a | ₹24b |
| Jun 30 2018 | n/a | n/a | ₹36b |
| Mar 31 2018 | ₹34m | ₹28m | ₹21b |
Vergütung im Vergleich zum Markt: DilipDie Gesamtvergütung ($USD656.49K) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Indian ($USD1.03M).
Entschädigung vs. Einkommen: DilipDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.
Geschäftsführer
Dilip Shanghvi (69 yo)
31.3yrs
Amtszeit
₹54,534,909
Vergütung
Mr. Dilip Shantilal Shanghvi serves as Chairman of Board of Directors of Taro Pharmaceutical Industries Ltd at Taro Pharmaceuticals U.S.A., Inc. He has been the Chairman of Sun Pharma Advanced Research Com...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| MD & Chairman of the Board | no data | ₹54.53m | 9.6% ₹ 348.6b | |
| Director of Corporate Development | no data | ₹65.30m | keine Daten | |
| Chief Financial Officer | 7yrs | ₹38.89m | keine Daten | |
| Executive Vice-President of Global Operations | no data | keine Daten | keine Daten | |
| EVP & Chief Information Officer | less than a year | keine Daten | keine Daten | |
| Head of Investor Relations | no data | keine Daten | keine Daten | |
| Company Secretary & Compliance Officer | 2.4yrs | keine Daten | keine Daten | |
| Chief Human Resources Officer | less than a year | keine Daten | keine Daten | |
| Chief Executive Officer of India Business | no data | keine Daten | keine Daten | |
| Executive VP | no data | keine Daten | 0.12% ₹ 4.4b | |
| Chief Executive Officer of North America Business | 7.8yrs | keine Daten | keine Daten | |
| Senior VP - Corporate Relations & CSR - India Regulatory Affairs | no data | keine Daten | keine Daten |
2.4yrs
Durchschnittliche Betriebszugehörigkeit
60yo
Durchschnittliches Alter
Erfahrenes Management: SUNPHARMADas Führungsteam des Unternehmens gilt als erfahren (2.3 Jahre durchschnittliche Betriebszugehörigkeit).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| MD & Chairman of the Board | 31.3yrs | ₹54.53m | 9.6% ₹ 348.6b | |
| Executive VP | less than a year | keine Daten | 0.12% ₹ 4.4b | |
| Non-Executive & Non-Independent Director | 30.4yrs | ₹1.90m | 1.8% ₹ 65.3b | |
| Non-Executive & Independent Director | 3.1yrs | ₹4.80m | keine Daten | |
| Non-Executive Independent Director | 6.1yrs | ₹7.60m | 0.00033% ₹ 12.0m | |
| Independent Director | less than a year | keine Daten | keine Daten | |
| Lead Independent Director | 3.1yrs | ₹8.50m | keine Daten | |
| Independent Director | 1.6yrs | ₹2.17m | keine Daten |
3.1yrs
Durchschnittliche Betriebszugehörigkeit
67.5yo
Durchschnittliches Alter
Erfahrener Vorstand: SUNPHARMADie Vorstandsmitglieder gelten als erfahren (3 Jahre durchschnittliche Amtszeit).